🇺🇸 FDA
Pipeline program

OCA IR 0.1 mg, 0,1 mg and 1,5 mg Placebo tablets, OCA 1.5 mg

747-308

Phase 3 small_molecule active

Quick answer

OCA IR 0.1 mg, 0,1 mg and 1,5 mg Placebo tablets, OCA 1.5 mg for Biliary Atresia, Post-hepatoportoenterostomy is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Biliary Atresia, Post-hepatoportoenterostomy
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials